Literature DB >> 6149343

Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: beneficial effect of low doses in early post-transplantation period.

G Klintmalm, S O Bohman, B Sundelin, H Wilczek.   

Abstract

To investigate whether cyclosporin (CsA) causes chronic renal damage 38 renal allograft biopsies were performed 1 to 4 years after transplantation in 28 CsA-treated patients, in the absence of rejection or acute CsA nephrotoxicity. Blind, semi-quantitative light microscopic examination showed that interstitial fibrosis plus tubular atrophy occurred more often in CsA-treated patients than in patients treated with azathioprine. The degree of interstitial fibrosis correlated with high cumulative CsA dose during the first 6 months of treatment, as well as with the number of acute CsA nephrotoxic episodes, which suggests that the findings are an effect of chronic CsA nephrotoxicity. Maintenance doses of CsA (2.3-10.7 mg/kg/day) seemed to contribute little to the renal damage. The pathogenesis of the observed lesions is not known. A high trough CsA level at the time of biopsy correlated with the degree of interstitial mononuclear cell infiltrate in the renal tissue. The results thus demonstrate chronic morphological changes in renal allografts from CsA-treated patients. Avoiding high CsA doses may be a way of preventing this side-effect. Until this has been confirmed, the risk of chronic renal damage must be taken into consideration when new clinical trials of CsA are being planned.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149343     DOI: 10.1016/s0140-6736(84)91166-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  30 in total

1.  The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine.

Authors:  P S Randhawa; R Shapiro; M L Jordan; T E Starzl; A J Demetris
Journal:  Am J Surg Pathol       Date:  1993-01       Impact factor: 6.394

2.  Transplantation.

Authors:  Thomas E Starzl
Journal:  JAMA       Date:  1986-10-17       Impact factor: 56.272

Review 3.  Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.

Authors:  A J Olyaei; A M de Mattos; W M Bennett
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

4.  Glomerular endothelial changes in cyclosporine A-treated rats: scanning and transmission electron microscopic studies.

Authors:  M Kobayashi; S Takaya; H Koie; K Nagai
Journal:  Jpn J Surg       Date:  1991-03

Review 5.  Molecular biology of type 1 (insulin-dependent) diabetes mellitus.

Authors:  A Lernmark
Journal:  Diabetologia       Date:  1985-04       Impact factor: 10.122

6.  Nephrotoxicity of cyclosporine in liver transplantation.

Authors:  S Iwatsuki; C O Esquivel; G B Klintmalm; R D Gordon; B W Shaw; T E Starzl
Journal:  Transplant Proc       Date:  1985-08       Impact factor: 1.066

7.  Cyclosporine-steroid combination therapy in 84 cadaveric renal transplants.

Authors:  R D Gordon; S Iwatsuki; B W Shaw; T E Starzl
Journal:  Am J Kidney Dis       Date:  1985-06       Impact factor: 8.860

8.  Cyclosporine-induced nephrotoxicity in deoxycorticosterone-NaCl treated rats.

Authors:  J M Wyss; M S Mozaffari; P L St John; D R Abrahamson
Journal:  Int J Exp Pathol       Date:  1993-12       Impact factor: 1.925

9.  Cyclosporin reduces renal prostanoid excretion in type 1 diabetic patients.

Authors:  V A Koivisto; M Leirisalo-Repo; R Pelkonen; U Turunen; J Rapola; L Viinikka; O Ylikorkala
Journal:  Acta Diabetol       Date:  1992       Impact factor: 4.280

10.  Acute and chronic renal failure in liver transplantation.

Authors:  J McCauley; D H Van Thiel; T E Starzl; J B Puschett
Journal:  Nephron       Date:  1990       Impact factor: 2.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.